Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LionHeart21: NPC-21 for CMV Prevention in Kidney Transplant
NCT04225923Phase 2Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of fiztasovimab in cytomegalovirus infection (CMV) (3 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoint: Incidence of CMV Disease or CMV Viremia at 16 weeks. Started Jun 2020; status: completed.
02
Drugs
fiztasovimab
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04225923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225923.